TITLE
Finasteride: a clinical review. 36 REFS

AUTHOR
Gormley GJ

ORGANISATION
Merck Research Laboratories, Rahway, NJ 07065-0914, USA.

SOURCE
Biomed Pharmacother 1995; 49 (7-8): 319-24

LANGUAGE OF PUBLICATION
English

ABSTRACT
Finasteride is the first of a new class of 5 alpha-reductase inhibitors which allows selective androgen deprivation affecting dihydrotestosterone (DHT) levels in target organs such as the prostate and scalp hair without effecting circulating levels of testosterone thus preserving the desired androgen mediated effects on muscle strength, bone density and sexual function. Finasteride has been demonstrated to produce significant effects in men with an enlarged prostate gland. The long-term data now emerging suggests that progression of benign prostatic hyperplasia (BPH) may be arrested providing additional long term benefits. Experimental uses in prostate cancer prevention and male pattern baldness offer new and exciting possibilities for this class of compounds. (AUTHOR)

MJTR: Enzyme Inhibitors. Finasteride.

MNTR: Alopecia DT. Enzyme Inhibitors TU. Finasteride ME. Finasteride TU. Hirsutism DT. Human. Male. Prostatic Hyperplasia DT. Prostatic Neoplasms DT. JOURNAL ARTICLE. REVIEW. REVIEW, TUTORIAL

RNUM: 0 (Enzyme Inhibitors); 98319-26-7 (Finasteride)

GEOT: FRANCE

IDEN: ISSN: 0753-3322. JOURNAL-CODE: A59. ENTRY-DATE: 960306. JOURNAL-SUBSET: M. IM-DATE: 9605.

ACCE: 96145521